I et randomiseret, komparativt fase III- forsøg med monoterapi var forekomsten af hjerteinsufficiens i VELCADE - gruppen den samme som i dexamethason- gruppen.
In a single agent Phase III randomised, comparative study the incidence of heart failure in the VELCADE group was similar to that in the dexamethasone group.